Abdulrahim A. Alzain

Dr. Abdulrahim A. Alzain

Institute for drug discovery, Leipzig University, Leipzig, Saxony, Germany
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
TSTagyedeen H. Shoaib
Tagyedeen H. Shoaib
NANihal Abdelmoniem
Nihal Abdelmoniem
RMRua M. Mukhtar
Rua M. Mukhtar
AAAmal Th. Alqhtani
Amal Th. Alqhtani
AAAbdullah Lafaa Alalawi
Abdullah Lafaa Alalawi
Abdulrahim A. AlzainAbdulrahim A. Alzain
Abdulrahim A. Alzain
The interaction between the tumor suppressor protein p53 and its negative regulator, the MDM2 oncogenic protein, has gained significant attention in cancer drug discovery. In this study, 120 lignans reported from Ferula sinkiangensis and Justicia procumbens were assessed for docking simulations on the active pocket of the MDM2 crystal structure bound to Nutlin-3a. The docking analysis identified nine compounds with higher docking scores than the co-crystallized reference. Subsequent AMDET profiling revealed satisfactory pharmacokinetic and safety parameters for these natural products. Three compounds, namely, justin A, 6-hydroxy justicidin A, and 6′-hydroxy justicidin B, were selected for further investigation due to their strong binding affinities of −7.526 kcal/mol, −7.438 kcal/mol, and −7.240 kcal/mol, respectively, which surpassed the binding affinity of the reference inhibitor Nutlin-3a (−6.830 kcal/mol). To assess the stability and reliability of the binding of the candidate hits, a molecular dynamics simulation was performed over a duration of 100 ns. Remarkably, the thorough analysis demonstrated that all the hits exhibited stable molecular dynamics profiles. Based on their effective binding to MDM2, favorable pharmacokinetic properties, and molecular dynamics behavior, these compounds represent a promising starting point for further refinement. Nevertheless, it is essential to synthesize the suggested compounds and evaluate their activity through in vitro and in vivo experiments.

1 May 2024 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
Mahmoud ElfakyMahmoud Elfaky
Mahmoud Elfaky
HOHassan M. Okairy
Hassan M. Okairy
Hossam AbdallahHossam Abdallah
Hossam Abdallah
AKAbdulrahman Koshak
Abdulrahman Koshak
GMGamal A. Mohamed
Gamal A. Mohamed
NSNoura M. seleem
Noura M. seleem
The rise of antibiotic resistance in bacteria is becoming a global concern, particularly due to the dwindling supply of new antibiotics. This situation mandates the discovery of new antimicrobial candidates. Plant-derived natural compounds have historically played a crucial role in the development of antibiotics, serving as a rich source of substances possessing antimicrobial properties. Numerous studies have supported the reputation of 6-gingerol, a prominent compound found in the ginger family, for its antibacterial properties. In this study, the antibacterial activities of 6-gingerol were evaluated against Gram-negative bacteria, Acinetobacter baumannii and Klebsiella pneumoniae, with a particular focus on the clinically significant Gram-negative Pseudomonas aeruginosa and Gram-positive bacteria Staphylococcus aureus. Furthermore, the anti-virulence activities were assessed in vitro, in vivo, and in silico. The current findings showed that 6-gingerol’s antibacterial activity is due to its significant effect on the disruption of the bacterial cell membrane and efflux pumps, as it significantly decreased the efflux and disrupted the cell membrane of S. aureus and P. aeruginosa. Furthermore, 6-gingerol significantly decreased the biofilm formation and production of virulence factors in S. aureus and P. aeruginosa in concentrations below MICs. The anti-virulence properties of 6-gingerol could be attributed to its capacity to disrupt bacterial virulence-regulating systems; quorum sensing (QS). 6-Gingerol was found to interact with QS receptors and downregulate the genes responsible for QS. In addition, molecular docking, and molecular dynamics (MD) simulation results indicated that 6-gingerol showed a comparable binding affinity to the co-crystalized ligands of different P. aeruginosa QS targets as well as stable interactions during 100 ns MD simulations. These findings suggest that 6-gingerol holds promise as an anti-virulence agent that can be combined with antibiotics for the treatment of severe infections.

14 August 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTagyedeen H. Shoaib
Tagyedeen H. Shoaib
WIWalaa Ibraheem
Walaa Ibraheem
MAMohammed Abdelrahman
Mohammed Abdelrahman
WOWadah Osman
Wadah Osman
ASAsmaa E. Sherif
Asmaa E. Sherif
Abdulrahim A. AlzainAbdulrahim A. Alzain
Abdulrahim A. Alzain
Triple-negative breast cancer (TNBC) is an aggressive malignancy that requires effective targeted drug therapy. In this study, we employedin silicomethods to evaluate the efficacy of seven approved drugs against human ck2 alpha kinase, a significant modulator of TNBC metastasis and invasiveness. Molecular docking revealed that the co-crystallized reference inhibitor 108600 achieved a docking score of (-7.390 kcal/mol). Notably, among the seven approved drugs tested, sunitinib, bazedoxifene, and etravirine exhibited superior docking scores compared to the reference inhibitor. Specifically, their respective docking scores were -10.401, -7.937, and -7.743 kcal/mol. Further analysis using MM/GBSA demonstrated that these three top-ranked drugs possessed better binding energies than the reference ligand. Subsequent molecular dynamics simulations identified etravirine, an FDA-approved antiviral drug, as the only repurposed drug that demonstrated a stable and reliable binding mode with the human ck2 alpha protein, based on various analysis measures including RMSD, RMSF, and radius of gyration. Principal component analysis indicated that etravirine exhibited comparable stability of motion as a complex with human ck2 alpha protein, similar to the co-crystallized inhibitor. Additionally, Density functional theory (DFT) calculations were performed on a complex of etravirine and a representative gold atom positioned at different sites relative to the heteroatoms of etravirine. The results of the DFT calculations revealed low-energy complexes that could potentially serve as guides for experimental trials involving gold nanocarriers of etravirine, enhancing its delivery to malignant cells and introducing a new drug delivery route. Based on the results obtained in this research study, etravirine shows promise as a potential antitumor agent targeting TNBC, warranting further investigation through experimental and clinical assessments.

2 February 2022 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
Abdulrahim A. AlzainAbdulrahim A. Alzain
Abdulrahim A. Alzain
FEFatima A. Elbadwi
Fatima A. Elbadwi
FAFatima O. Alsamani
Fatima O. Alsamani
The global expansion of COVID-19 and the mutations of severe acute respiratory syndrome coronavirus necessitate quick development of treatment and vaccination. Because the androgen-responsive serine protease TMPRSS2 is involved in cleaving the SARS-CoV-2 spike protein allowing the virus to enter the cell, therefore, direct TMPRSS2 inhibition will inhibit virus activation and disease progression which make it an important target for drug discovery. In this study, a homology model of TMPRSS2 protein was initially developed. Then, we used the fragment-based drug design (FBDD) technique to develop effective TMPRSS2 inhibitors. Over a half-million fragments from the enamine database were screened for their binding ability to target protein, and then best-scoring fragments were linked to building new molecules with a good binding affinity. XP docking and MM-GBSA studies revealed 10 new formed molecules with docking score ≤ −14.982 kcal/mol compared to ambroxol (control) with a docking score of −6.464 kcal/mol. Finally, molecular dynamics (MD) and density functional theory (DFT) were calculated for the top 3 molecules.

27 December 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
AKAbdulrahman Koshak
Abdulrahman Koshak
HOHassan M. Okairy
Hassan M. Okairy
Mahmoud ElfakyMahmoud Elfaky
Mahmoud Elfaky
Hossam AbdallahHossam Abdallah
Hossam Abdallah
Gamal Abd AllahGamal Abd Allah
Gamal Abd Allah
SNShaimaa I. Nazeih
Shaimaa I. Nazeih

13 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
NANihal AbdElmoniem
Nihal AbdElmoniem
MAMarwa H. Abdallah
Marwa H. Abdallah
RMRua M. Mukhtar
Rua M. Mukhtar
FMFatima Moutasim
Fatima Moutasim
AAAhmed Rafie Ahmed
Ahmed Rafie Ahmed
Abdulrahim A. AlzainAbdulrahim A. Alzain
Abdulrahim A. Alzain
Breast cancer (BC) is one of the main types of cancer that endangers women’s lives. The characteristics of triple-negative breast cancer (TNBC) include a high rate of recurrence and the capacity for metastasis; therefore, new therapies are urgently needed to combat TNBC. Dual targeting HDAC6 and Hsp90 has shown good synergistic effects in treating metastatic TNBC. The goal of this study was to find potential HDAC6 and Hsp90 dual inhibitors. Therefore, several in silico approaches have been used. An e-pharmacophore model generation based on the HDAC6-ligand complex and subsequently a pharmacophore-based virtual screening on 270,450 natural compounds from the ZINC were performed, which resulted in 12,663 compounds that corresponded to the obtained pharmacophoric hypothesis. These compounds were docked into HDAC6 and Hsp90. This resulted in the identification of three compounds with good docking scores and favorable free binding energy against the two targets. The top three compounds, namely ZINC000096116556, ZINC000020761262, and ZINC000217668954, were further subjected to ADME prediction and molecular dynamic simulations, which showed promising results in terms of pharmacokinetic properties and stability. As a result, these three compounds can be considered potential HDAC6 and Hsp90 dual inhibitors and are recommended for experimental evaluation.